ClinicalTrials.gg
CompletedNCT00462462Updated Jan 15, 2015Results posted

Systemic and Local Diffusion of Ethanol After Administration of Ethanol 96% Formulated in a Gel and Ethanol 98% Solution by the Percutaneous Route, in Patients With Congenital Venous Malformations:Pharmacokinetic, Pharmacodynamic and Clinical Study.

A Phase 2 interventional study of Ethanol 96% Gel and Ethanol 98% Solution in Congenital Venous Malformation, sponsored by Orfagen. Completed at 2 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2015-01-15.

Sponsored by Orfagen · Phase 2 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

Absolute ethanol has been used "off-label" as an unmodified formulation (solution) in Congenital Venous Malformations (CVM). Despite its effectiveness, absolute ethanol appears difficult to handle because of its high diffusion capacity outside the CVM and in the blood circulation. A less diffusible ethanol-based product (ethanol gel) has been developed in order to minimize systemic and local diffusion capacities of ethanol. Therefore, the pharmacokinetic parameters and their clinical and paraclinical outcomes between ethanol gel 96% and absolute ethanol need to be carried out.

FDA Office of Orphan Products Development (FDA OOPD) : Funding source.

02

Conditions studied

  • Congenital Venous Malformation
03

In context

Lead sponsor

Orfagen is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of both sexes, of at least 12 years of age,
  • For women of , negative pregnancy test at baseline,
  • Patients with one clinically and radiologically (MRI) documented lesion diagnosed as CVM (pure or predominant),
  • Patients for which an embolosclerotherapy by the percutaneous route is indicated as therapy of the test lesion, or for which previous treatments (i.e. surgery, embolosclerotherapy, laser) have been unsuccessful or insufficient,
  • Patients with CVM lesional size of at least 12 cm3 (maximum craniocaudal dimension X mean dimension of 3 transverse equispaced measurements X mean dimension of 3 deepness equispaced measurements dimension) at MRI,
  • Patients with focal or multifocal CVM lesion, i.e. with one or several well-interconnecting venous spaces and well-defined margins,
  • Patients or parents able to follow study instructions and attend study visits,
  • Written from the patients or parents.

Exclusion criteria

Exclusion criteria:

  • Patients under 12 years of age,
  • Pregnant women, nursing mothers and women of with no reliable from more than 2 months,
  • Women of childbearing potential with a positive pregnancy test at baseline,
  • Patients with CVM of non venous predominance,
  • Patients with CVM that are not reachable by the percutaneous route,
  • Patients with extensive superficial skin CVM (i.e. with high risk of skin necrosis),
  • Patients with a test lesion adjacent to major nerves (e.g. facial nerve in the parotid region, intramuscular regions adjacent to major nerves),
  • Patients with facial CVM or bone involvement,
  • Patients with small CVM lesion (\<12 cm3 at MRI),
  • Patients requiring more than 1 ml/Kg body weight (b.w.) in USA or more than 0.5 ml/Kg b.w. in France, or more than 30 mL of absolute ethanol to infuse,
  • Patients with a known allergy to one of the components of the test products,
  • Patients with a suspected allergy to iodinate.ed products,
  • Patients with abnormal clotting parameters (, partial thromboplastin, ),
  • Patients with an active inflammatory episode of the test lesion (i.e. acute or subacute swelling of the test lesion),
  • Patients with complex malformations (e.g. Klippel-Trenaunay syndrome, Blue Rubber Bled Nevus syndrome, Muco-cutaneous familial venous malformations, Mafucci's syndrome),
  • Patients in which a surgery, laser therapy or embolosclerotherapy of the test lesion has been performed within the last 12 weeks prior to study entry,
  • Asthmatic patients who require daily medications,
  • Patients with a non treated or non stabilized cardiac disease,
  • Patients with a suspected right-left shunt,
  • Patients with an intercurrent condition or a concomitant treatment which may interfere with a good conduct or the evaluation parameters of the study,
  • Patients who participated in a study within the 12 weeks prior to study entry,
  • Patients or parents who are not able or willing to follow the study instructions,
  • Patients or parents who refuse to give written .
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 2
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    1

    Ethanol gel

    Drug: Ethanol 96% Gel

  • Active comparator
    2

    Ethanol solution

    Drug: Ethanol 98% Solution

06

What researchers measure

Primary outcomes

  1. Systemic Exposure to Ethanol With the Two Test Products: Determination of the Maximum Plasma Concentration (Cmax)

    Blood samples were performed, just before infusion, then 5 min, 10 min, 20 min, 40 min, 60 min, 90 min, and 120 min after infusion at the first site, then every 60 min onwards until ethanol levels are found under the detection limit. Cmax was estimated directly from experimental data. If all the ethanol concentrations of a patient was below the limit of quantification of the laboratory (LOQ), Cmax was reported as LOQ/2 for this patient.

    Time frame: Baseline visit (just before and during test product infusion procedure)

Secondary outcomes

  1. Systemic (Cardiopulmonary, Hematological, Metabolic) and Local Outcome of the Two Test Products.

    Time frame: Study end

  2. Change in Volume of Congenital Venous Malformation (CVM) From Screening to Study End (Day 112 Visit).

    Time frame: Screening and study end (Day 112)

  3. Patient Benefit

    Time frame: study end

07

Results

Posted Dec 12, 2014

Participant flow

Participant flow — Overall Study
MilestoneL0122 Gel GroupAbsolute Ethanol Group
Started1714
Completed1713
Not completed01
Withdrew: Physician decision01

Outcome measures

PrimarySystemic Exposure to Ethanol With the Two Test Products: Determination of the Maximum Plasma Concentration (Cmax)

Blood samples were performed, just before infusion, then 5 min, 10 min, 20 min, 40 min, 60 min, 90 min, and 120 min after infusion at the first site, then every 60 min onwards until ethanol levels are found under the detection limit. Cmax was estimated directly from experimental data. If all the ethanol concentrations of a patient was below the limit of quantification of the laboratory (LOQ), Cmax was reported as LOQ/2 for this patient.

Time frame:
Baseline visit (just before and during test product infusion procedure)
Reported as:
Mean · g/L
Systemic Exposure to Ethanol With the Two Test Products: Determination of the Maximum Plasma Concentration (Cmax)
g/LL0122 Gel GroupAbsolute Ethanol Group
Systemic Exposure to Ethanol With the Two Test Products: Determination of the Maximum Plasma Concentration (Cmax)0.0604 (0.015 to 0.4)0.202 (0.05 to 0.940)
SecondarySystemic (Cardiopulmonary, Hematological, Metabolic) and Local Outcome of the Two Test Products.
Time frame:
Study end

Results for this outcome have not been posted.

SecondaryChange in Volume of Congenital Venous Malformation (CVM) From Screening to Study End (Day 112 Visit).
Time frame:
Screening and study end (Day 112)
Reported as:
Mean · cm3
Change in Volume of Congenital Venous Malformation (CVM) From Screening to Study End (Day 112 Visit).
cm3L0122 Gel GroupAbsolute Ethanol Group
Change in Volume of Congenital Venous Malformation (CVM) From Screening to Study End (Day 112 Visit).-10.328 ± 36.667-126.944 ± 367.229
SecondaryPatient Benefit
Time frame:
study end

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
L0122 Gel Group—2/17 (11.8%)12/17 (70.6%)
Absolute Ethanol Group—4/14 (28.6%)10/14 (71.4%)
Most frequent serious events
Most frequent serious events
EventL0122 Gel GroupAbsolute Ethanol Group
Blood ethanol increasedInvestigations0/173/14
Arteriovenous malformationCongenital, familial and genetic disorders2/171/14
Most frequent other events
Showing 10 of 28
Most frequent other events
EventL0122 Gel GroupAbsolute Ethanol Group
CoagulopathyBlood and lymphatic system disorders1/175/14
Procedural hypotensionInjury, poisoning and procedural complications2/174/14
HaemolysisBlood and lymphatic system disorders2/174/14
Injection site paraesthesiaGeneral disorders3/170/14
PainGeneral disorders1/171/14
Complication of device insertionGeneral disorders0/171/14
Injection site haematomaGeneral disorders0/171/14
Injection site painGeneral disorders0/171/14
Injection site ulcerGeneral disorders0/171/14
Airway complication of anaesthesiaInjury, poisoning and procedural complications0/171/14

Baseline characteristics

Baseline characteristics of the patients who received the study product (L0122 gel or Absolute Ethanol), whichever the amount of product was infused . 32 patients were enrolled in the study, but 31 received the study product (1 patient not treated; inclusion mistake).

Age, Categorical
Age, Categorical(Participants)L0122 Gel GroupAbsolute Ethanol GroupTotal
<=18 years527
Between 18 and 65 years111122
>=65 years112
Sex: Female, Male
Sex: Female, Male(Participants)L0122 Gel GroupAbsolute Ethanol GroupTotal
Female11819
Male6612
Region of Enrollment
Region of Enrollment(participants)L0122 Gel GroupAbsolute Ethanol GroupTotal
France8715
United States9716
Lesional volume
Lesional volume(cm3)L0122 Gel GroupAbsolute Ethanol GroupTotal
Mean82.712 ± 156.316561.472 ± 1147.306298.926 ± 801.306
08

Study locations

2 sites
  • Johns Hopkins Medical Institutions
    Baltimore, Maryland 21287, United States
  • Hôpital Bretonneau Service de neuroradiologie
    Tours Cedex 1, 37044, France
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2014, 4 years 6 months after primary completion. A results delay was requested in Mar 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2007
First posted
Apr 19, 2007
Start
May 2007
Primary completionActual
Jun 2010
CompletionActual
Jun 2010
Results delay requested
Mar 29, 2013
Results first posted
Dec 12, 2014
Last update
Jan 15, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00462462
Lead sponsor
Orfagen
Collaborators
FDA Office of Orphan Products Development
Responsible party
Sponsor
First posted
Apr 19, 2007
Start date
May 2007
Primary completion
Jun 2010
Completion
Jun 2010
Results posted
Dec 12, 2014
Last update
Jan 15, 2015

Study contacts

PATRICK DUPUY, MD
study director · ORFAGEN LABORATORIES (France)
SALLY E MITCHELL, MD
principal investigator · Johns Hopkins Medical Institution (Baltimore, USA)
Denis HERBRETEAU, MD
principal investigator · Hôpital Bretonneau (Tours, France)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ethanol

Start the discussion